Gilead Goes Full Steam Ahead In Oncology With Big Lung Cancer Push

Islatravir/Lenacapavir Program Under Way Again

 
• By Alaric DeArment
  
In its third quarter earnings, Gilead highlighted its drug development efforts in oncology, infectious and inflammatory diseases • Source: Shutterstock

More from Earnings

More from Business